Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility

被引：29
作者：
Van Baelen, Kurt [1 ]
Van Eygen, Veerle [1 ]
Rondelez, Evelien [1 ]
Stuyver, Lieven J. [1 ]
机构：
[1] Virco BVBA, B-2800 Mechelen, Belgium
来源：
AIDS | 2008年 / 22卷 / 14期
关键词：
D O I：
10.1097/QAD.0b013e32830f9703
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The contribution of clade-specific polymorphisms in the HIV-1 integrase gene towards integrase inhibitor phenotypic susceptibility was tested on 137 clinical isolates, of which 60 were non-clade B strains. Control Q148R mutant virus showed fold change values of 17.85 +/- 2.77 and 88.94 +/- 9.02 for raltegravir and elvitegravir, respectively, whereas the average fold change for the clinical samples was 0.91 +/- 0.40, and 0.84 +/- 0.37. Phenotypic testing proved that clade-specific integrase polymorphisms do not contribute to reduced susceptibility towards integrase inhibitors.
引用
收藏
页码：1877 / 1880
页数：4
相关论文
共 50 条
  • [41] Polymorphism of HIV-2 integrase gene and in vitro phenotypic susceptibility of HIV-2 clinical isolates to integrase inhibitors:: raltegravir and evitegravir
    Roquebert, B.
    Damond, F.
    Collin, G.
    Matheron, S.
    Taieb, A.
    Peytavin, G.
    Bernard, A.
    Campa, P.
    Chene, G.
    Brun-Vezinet, F.
    Descamp, D.
    [J]. ANTIVIRAL THERAPY, 2007, 12 : S92 - S92
  • [42] Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness
    Abram, Michael E.
    Hluhanich, Rebecca M.
    Goodman, Derrick D.
    Andreatta, Kristen N.
    Margot, Nicolas A.
    Ye, Linda
    Niedziela-Majka, Anita
    Barnes, Tiffany L.
    Novikov, Nikolai
    Chen, Xiaowu
    Svarovskaia, Evguenia S.
    McColl, Damian J.
    White, Kirsten L.
    Miller, Michael D.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (06) : 2654 - 2663
  • [43] HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors
    Alessandri-Gradt, E.
    Collin, G.
    Tourneroche, A.
    Bertine, M.
    Leoz, M.
    Charpentier, C.
    Unal, G.
    Descamps, D.
    Plantier, J. C.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (09) : 2431 - 2437
  • [44] Comprehensive Review on Different Analytical Techniques for HIV 1-Integrase Inhibitors: Raltegravir, Dolutegravir, Elvitegravir and Bictegravir
    Jain, Priti
    Thota, Anusha
    Saini, Pawan K.
    Raghuvanshi, Rajeev Singh
    [J]. CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY, 2024, 54 (02) : 401 - 415
  • [45] Clinical Pharmacology Profile of Raltegravir, an HIV-1 Integrase Strand Transfer Inhibitor
    Brainard, Diana M.
    Wenning, Larissa A.
    Stone, Julie A.
    Wagner, John A.
    Iwamoto, Marian
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (10) : 1376 - 1402
  • [46] Minimal sequence variability of the region of HIV-1 integrase targeted by the Abbott RealTime HIV-1 viral load assay in clinical specimens with reduced susceptibility to raltegravir
    Young, Thomas P.
    Napolitano, Laura A.
    Paquet, Agnes C.
    Parkin, Neil T.
    Fransen, Signe
    Trinh, Roger
    Haddad, Mojgan
    Hackett, John, Jr.
    Cloherty, Gavin A.
    [J]. JOURNAL OF VIROLOGICAL METHODS, 2013, 193 (02) : 693 - 696
  • [47] COMPARISON OF IMMUNOLOGICAL AND VIROLOGICAL RECOVERY OF RALTEGRAVIR, ELVITEGRAVIR AND DOLUTEGRAVIR IN HIV-1 INFECTED NAIVE PATIENTS
    Sarigul, Figen
    User, U.
    Oztoprak, N.
    [J]. ACTA MEDICA MEDITERRANEA, 2019, 35 (06): : 3077 - 3084
  • [48] Serotyping HIV-1 with V3 peptides: detection of high avidity antibodies presenting clade-specific reactivity
    Casseb, J
    Katzenstein, D
    Winters, M
    Brigido, LFM
    Duarte, AJS
    Hendry, RM
    [J]. BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2002, 35 (03) : 369 - 375
  • [49] Biochemical and Pharmacological Analyses of HIV-1 Integrase Flexible Loop Mutants Resistant to Raltegravir
    Metifiot, Mathieu
    Maddali, Kasthuraiah
    Naumova, Alena
    Zhang, Xuemin
    Marchand, Christophe
    Pommier, Yves
    [J]. BIOCHEMISTRY, 2010, 49 (17) : 3715 - 3722
  • [50] Structural models of HIV-1 integrase and DNA in complex with S/GSK1349572, raltegravir or elvitegravir: structure-based rationale for INI resistance profiles
    Deanda, F. G.
    Hattori, K.
    Yoshinaga, T.
    Kawasuji, T.
    Underwood, M. R.
    [J]. ANTIVIRAL THERAPY, 2010, 15 : A73 - A73
12345